Search hospitals

>

Georgia

>

Atlanta

Emory University Hospital/Winship Cancer Institute

Claim this profile

Atlanta, Georgia 30322

Global Leader in Cancer

Global Leader in Breast Cancer

Conducts research for Lung Cancer

Conducts research for Multiple Myeloma

Conducts research for Pancreatic Cancer

1082 reported clinical trials

100 medical researchers

Photo of Emory University Hospital/Winship Cancer Institute in AtlantaPhoto of Emory University Hospital/Winship Cancer Institute in AtlantaPhoto of Emory University Hospital/Winship Cancer Institute in Atlanta

Summary

Emory University Hospital/Winship Cancer Institute is a medical facility located in Atlanta, Georgia. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Multiple Myeloma, Pancreatic Cancer and other specialties. Emory University Hospital/Winship Cancer Institute is involved with conducting 1,082 clinical trials across 817 conditions. There are 100 research doctors associated with this hospital, such as Jonathan Cohen, MD, Ticiana A. Leal, Conor Steuer, and Olatunji Alese.

Area of expertise

1

Cancer

Global Leader

Emory University Hospital/Winship Cancer Institute has run 163 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II
2

Breast Cancer

Global Leader

Emory University Hospital/Winship Cancer Institute has run 144 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
HER2 negative
Stage III

Top PIs

Clinical Trials running at Emory University Hospital/Winship Cancer Institute

Lung Cancer

Breast Cancer

Prostate Cancer

Skin Cancer

Breast cancer

Multiple Myeloma

Ovarian Cancer

Colorectal Cancer

Liver Cancer

Pancreatic Cancer

Image of trial facility.

Ceralasertib + Durvalumab

for Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.

Recruiting

2 awards

Phase 3

10 criteria

Image of trial facility.

Radiation Therapy

for Brain Metastasis

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.

Recruiting

2 awards

Phase 3

12 criteria

Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.

Recruiting

2 awards

Phase 3

31 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Emory University Hospital/Winship Cancer Institute?

Where is Emory University Hospital/Winship Cancer Institute located?

Who should I call to ask about financial aid or insurance network?

What insurance does Emory University Hospital/Winship Cancer Institute accept?

What awards or recognition has Emory University Hospital/Winship Cancer Institute received?